An equianalgesic chart provides a list of doses of analgesic agents, both oral and parenteral (IV, subcutaneous, and intramuscular), that are approximately equal to each other in ability to provide pain relief. A client was receiving 1 mg of oxymorphone, how much oxymorphone should the provider prescribe at discharge to ensure continued pain relief and prevent withdrawal?

Rationale: A. Prescribing 100 mg of oxymorphone for a patient who was previously receiving 1 mg would be an extremely dangerous overdose, potentially causing severe respiratory depression, sedation, coma, or death. This dose does not align with equianalgesic principles, which rely on maintaining continuity of analgesic effect. B. Similarly, prescribing 75 mg represents a dramatic increase over the previous effective dose. Equianalgesic dosing is intended to ensure comparable pain control, and a 75-fold increase is unsafe and medically inappropriate. C. The patient was receiving 1 mg of oxymorphone prior to discharge. To maintain pain control and prevent withdrawal, the same dose should be continued unless clinical factors, such as breakthrough pain, side effects, or changes in pain severity, warrant an adjustment. Maintaining the current dose ensures stable analgesia and prevents withdrawal symptoms, which can include agitation, anxiety, sweating, nausea, vomiting, abdominal cramps, and muscle aches. Continuity of opioid therapy is critical in avoiding these potentially distressing symptoms. D. Prescribing 10 mg represents a tenfold increase, which is extremely unsafe and not supported by equianalgesic dosing guidelines for a patient previously on 1 mg. Such a dose could result in life-threatening respiratory depression or opioid toxicity.